CABA
NASDAQ · Biotechnology
Cabaletta Bio Inc
$2.76
+0.07 (+2.60%)
Open$2.73
Previous Close$2.69
Day High$2.79
Day Low$2.69
52W High$3.78
52W Low$0.99
Volume—
Avg Volume3.27M
Market Cap306.12M
P/E Ratio—
EPS$-2.51
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+1,341.7% upside
Current
$2.76
$2.76
Target
$39.79
$39.79
$29.42
$39.79 avg
$58.63
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 65.93M | 59.67M | 56.91M |
| Net Income | 10.90M | 11.06M | 10.11M |
| Profit Margin | 16.5% | 18.5% | 17.8% |
| EBITDA | 19.62M | 16.47M | 16.10M |
| Free Cash Flow | 6.94M | 6.70M | 7.67M |
| Rev Growth | +19.8% | +7.9% | +20.9% |
| Debt/Equity | 0.22 | 0.21 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |